Carisma Therapeutics, Inc.
CARM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | 2.1% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | 100% | 81.7% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -232.6% | -464.4% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -248.5% | -482.8% |
| EPS Diluted | 1.07 | -0.23 | -0.22 | -0.42 |
| % Growth | 565.2% | -4.5% | 47.6% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |